BillionToOne Stock
BillionToOne is a next-generation molecular diagnostics company focused on enhancing disease detection and quantification through its proprietary Quantitative Counting Technology (QCT), which enables precise analysis of DNA molecules at the single base-pair level for applications in prenatal screening and oncology.
Sign up for SecondMarket™ to view the market and buy or sell BillionToOne Stock
Buy + SellBillionToOne Funding
Sign up to gain insights into BillionToOne funding history, including the funding round, time period, and amount raised.
Sign Up to Unlock the DataDate | Financing Round | Amount | Price per share* | Valuation* |
---|---|---|---|---|
Sep 19, 2022 | Series C | 30.00M | ||
Mar 30, 2022 | Series C | 125.00M | ||
Jun 14, 2021 | Series B | 16.02M | ||
Jun 14, 2021 | Series B | 55.00M | ||
Mar 13, 2019 | Series A | 15.00M | ||
Mar 13, 2019 | Series A | 902.43K | ||
Mar 13, 2019 | Series A | 50.00K | ||
Mar 13, 2019 | Series A | 910.00K | ||
Mar 13, 2019 | Series A | 100.00K | ||
Mar 13, 2019 | Series A | 537.57K |
See BillionToOne Valuations + Financials
*Sample data + company shown for illustrative purposes only
Gain insights Into BillionToOne Stock Valuation + Share Prices
View real-time Tape D™ data on BillionToOne stock including most recent valuation and historical share price information.
Are you an institutional investor or employee shareholder? Sign up to the SecondMarket™ trading platform.
Get StartedBillionToOne Management Team
CEO
David Lortscher
Director
Larry Illg
Director
Richard J. Boyle